Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1971 Oct;68(10):2350–2353. doi: 10.1073/pnas.68.10.2350

Radioimmunoassay of Human Fibrinopeptide A

H L Nossel 1,2, L R Younger 1,2, G D Wilner 1,2, T Procupez 1,2, R E Canfield 1,2, V P Butler Jr 1,2
PMCID: PMC389419  PMID: 5289869

Abstract

A radioimmunoassay capable of measuring 1 pmole of human fibrinopeptide A has been developed, and should prove useful to detect the release of this peptide from fibrinogen during the coagulation process. Antibodies to fibrinopeptide A were produced by injecting New Zealand white rabbits with a mixture of Freund's adjuvant and native fibrinopeptide coupled to human albumin. N-Tyrosyl fibrinopeptide A was synthesized by the solid-phase method, and was iodinated with 125I by the Chloramine-T method. 48-73% of the radiolabeled peptide could be bound by the serum of a rabbit immunized with the fibrinopeptide-albumin preparation. Antibody-bound peptide was precipitated by dioxane and was thus separated from unbound peptide. The addition of excess native fibrinopeptide to the radiolabeled material prevented its binding to serum. Native fibrinopeptide A and synthetic fibrinopeptide A were identical in their ability to prevent binding, whereas fibrinogen was from 1/25,000 to 1/50,000 as effective on a weight basis. Plasma filtered through a membrane relatively impermeable to molecules larger than a molecular weight of 34,000 showed no fibrinopeptide reactivity, whereas a similar filtrate of serum gave quantitative recovery of fibrinopeptide reactivity.

Keywords: fibrinogen, blood coagulation, peptide synthesis, pmoles detected, dysfibrinogenemia

Full text

PDF
2350

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BAILEY K., BETTELHEIM F. R., LORAND L., MIDDLEBROOK W. R. Action of thrombin in the clotting of fibrinogen. Nature. 1951 Feb 10;167(4241):233–234. doi: 10.1038/167233a0. [DOI] [PubMed] [Google Scholar]
  2. BETTELHEIM F. R., BAILEY K. The products of the action of thrombin on fibrinogen. Biochim Biophys Acta. 1952 Nov;9(5):578–579. doi: 10.1016/0006-3002(52)90213-8. [DOI] [PubMed] [Google Scholar]
  3. BETTELHEIM F. R. The clotting of fibrinogen. II. Fractionation of peptide material liberated. Biochim Biophys Acta. 1956 Jan;19(1):121–130. doi: 10.1016/0006-3002(56)90393-6. [DOI] [PubMed] [Google Scholar]
  4. Blombäck B., Blombäck M., Edman P., Hessel B. Human fibrinopeptides. Isolation, characterization and structure. Biochim Biophys Acta. 1966 Feb 28;115(2):371–396. doi: 10.1016/0304-4165(66)90437-5. [DOI] [PubMed] [Google Scholar]
  5. Blombäck M., Blombäck B., Mammen E. F., Prasad A. S. Fibrinogen Detroit--a molecular defect in the N-terminal disulphide knot of human fibrinogen? Nature. 1968 Apr 13;218(5137):134–137. doi: 10.1038/218134a0. [DOI] [PubMed] [Google Scholar]
  6. GOODFRIEND T. L., LEVINE L., FASMAN G. D. ANTIBODIES TO BRADYKININ AND ANGIOTENSIN: A USE OF CARBODIIMIDES IN IMMUNOLOGY. Science. 1964 Jun 12;144(3624):1344–1346. doi: 10.1126/science.144.3624.1344. [DOI] [PubMed] [Google Scholar]
  7. Goodfriend T. L., Ball D. L. Radioimmunoassay of bradykinin: chemical modification to enable use of radioactive iodine. J Lab Clin Med. 1969 Mar;73(3):501–511. [PubMed] [Google Scholar]
  8. HUNTER W. M., GREENWOOD F. C. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature. 1962 May 5;194:495–496. doi: 10.1038/194495a0. [DOI] [PubMed] [Google Scholar]
  9. Herzig R. H., Ratnoff O. D., Shainoff J. R. Studies on a procoagulant fraction of southern copperhead snake venom: the preferential release of fibrinopeptide B. J Lab Clin Med. 1970 Sep;76(3):451–465. [PubMed] [Google Scholar]
  10. LORAND L. Fibrino-peptide. Biochem J. 1952 Oct;52(2):200–203. doi: 10.1042/bj0520200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Mammen E. F., Prasad A. S., Barnhart M. I., Au C. C. Congenital dysfibrinogenemia: fibrinogen Detroit. J Clin Invest. 1969 Feb;48(2):235–249. doi: 10.1172/JCI105980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Merrifield R. B. Solid-phase peptide synthesis. Adv Enzymol Relat Areas Mol Biol. 1969;32:221–296. doi: 10.1002/9780470122778.ch6. [DOI] [PubMed] [Google Scholar]
  13. Nossel H. L., Rubin H., Drillings M., Hsieh R. Inhibition of Hageman factor activation. J Clin Invest. 1968 May;47(5):1172–1180. doi: 10.1172/JCI105806. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. RATNOFF O. D. Hemostatic mechanisms in liver disease. Med Clin North Am. 1963 May;47:721–736. doi: 10.1016/s0025-7125(16)33574-x. [DOI] [PubMed] [Google Scholar]
  15. Thomas K., Ferin J. A new rapid radioimmunoassay for HCG (LH, ICSH) in plasma using dioxan. J Clin Endocrinol Metab. 1968 Nov;28(11):1667–1670. doi: 10.1210/jcem-28-11-1667. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES